Polymorphisms of cancer stem cell marker gene CD133 are associated with susceptibility and prognosis of gastric cancer

Future Oncol. 2017 May;13(11):979-989. doi: 10.2217/fon-2017-0019. Epub 2017 Feb 24.

Abstract

Aim: This study was aimed to investigate the associations between single nucleotide polymorphisms of cancer stem cell marker genes, CD44 and CD133, and susceptibility and prognosis of gastric cancer.

Patients & methods: Five single nucleotide polymorphisms in CD44 and CD133 genes were genotyped in 898 gastric cancer cases and 992 controls.

Results: The A/C or C/C genotypes of CD133 rs2240688 were associated with decreased risk of gastric cancer comparing with the A/A genotype (odds ratio: 0.81; 95% CI: 0.67-0.97; p = 0.023). The T allele of CD133 rs3130 predicted a worse survival for gastric cancer patients receiving tumorectomy (hazard ratio: 1.28; 95% CI: 1.04-1.58; p = 0.020), independent from tumor node metastasis stage, vessel invasion and postoperational chemotherapy.

Conclusion: CD133 polymorphisms are promising biomarkers for genetic susceptibility and prognosis prediction of gastric cancer.

Keywords: CD133; CD44; gastric cancer; overall survival; polymorphism; susceptibility.

MeSH terms

  • AC133 Antigen / genetics*
  • Aged
  • Alleles
  • Biomarkers, Tumor*
  • Female
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Hyaluronan Receptors / genetics
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplastic Stem Cells / metabolism*
  • Odds Ratio
  • Polymorphism, Single Nucleotide*
  • Prognosis
  • Stomach Neoplasms / diagnosis
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / mortality*
  • Stomach Neoplasms / therapy

Substances

  • AC133 Antigen
  • Biomarkers, Tumor
  • Hyaluronan Receptors